Antibody-drug Conjugates for Breast Cancer Treatment
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The use of antibody-drug conjugates is expected to transform the management of human malignancy. Antibody-drug conjugates for cancer treatment are designed to deliver anticancer drugs to tumor cells. The main components of such conjugates are a monoclonal antibody that binds to a tumor antigen, an anticancer drug to inhibit tumor cell growth and a linker that serves to conjugate the antibody and drug. The antibody-drug conjugates developed and approved for breast cancer treatment are ado-trastuzumab emtansine, (fam)-trastuzumab deruxtecan-nxki and sacituzumab govitecan. The mechanisms of action, clinical uses and toxic effects of these antibody-drug conjugates are discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Recent patents on anti-cancer drug discovery - 18(2022), 2 vom: 21., Seite 108-113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sheikh, M Saeed [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.01.2023 Date Revised 02.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574892817666220729121205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34428963X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34428963X | ||
| 003 | DE-627 | ||
| 005 | 20231226022426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574892817666220729121205 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM34428963X | ||
| 035 | |a (NLM)35909271 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sheikh, M Saeed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody-drug Conjugates for Breast Cancer Treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The use of antibody-drug conjugates is expected to transform the management of human malignancy. Antibody-drug conjugates for cancer treatment are designed to deliver anticancer drugs to tumor cells. The main components of such conjugates are a monoclonal antibody that binds to a tumor antigen, an anticancer drug to inhibit tumor cell growth and a linker that serves to conjugate the antibody and drug. The antibody-drug conjugates developed and approved for breast cancer treatment are ado-trastuzumab emtansine, (fam)-trastuzumab deruxtecan-nxki and sacituzumab govitecan. The mechanisms of action, clinical uses and toxic effects of these antibody-drug conjugates are discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a TROP-2. | |
| 650 | 4 | |a ado-trastuzumab emtansine | |
| 650 | 4 | |a sacituzumab govitecan | |
| 650 | 4 | |a trastuzumab deruxtecan | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Ado-Trastuzumab Emtansine |2 NLM | |
| 650 | 7 | |a SE2KH7T06F |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 700 | 1 | |a Huang, Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent patents on anti-cancer drug discovery |d 2006 |g 18(2022), 2 vom: 21., Seite 108-113 |w (DE-627)NLM174758006 |x 2212-3970 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:2 |g day:21 |g pages:108-113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574892817666220729121205 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 2 |b 21 |h 108-113 | ||